Member Info for Wiggly

"Just suppose that a significant number of people have some FAP near healthy important organs.

Can you imagine dosing straight dox direct to the heart?

Dr. Coughlin, Sept 2023.

Her words, not mine and not any FUD spreader.

I am delighted to have the opportunity to work with them to complete the hugely successful dose escalation study and move into the dose expansion study in soft tissue sarcoma patients later this year.

"Beyond that we have potential to exploit AVA6000 to treat other cancers such as breast and ovarian and a wealth of opportunities to build our pipeline and partnerships. I am looking forward to working with the team on this strategy at this very exciting time."

Tim

I think the BOD would be in serious legal trouble if the data was anything other than absolute blockbuster.

They could inform the market that they are in several advanced partnering discussions.

As we head into a pivotal week, it is worth digesting the below again, word for word.

"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.

"Not only are the initial safety data emerging from the AVA6000 Phase 1 study, across all dose cohorts, remarkably good, but targeted release of doxorubicin in the tumour has been confirmed both by analysis of tumour biopsies and now by clear clinical responses.

"Even at this early stage and in this patient group, we have a confirmed, significant reduction in tumour volume in a patient with soft tissue sarcoma, as well as other positive signals across a number of patients.

In light of the highly positive Phase 1a data, the Company has adapted its clinical development strategy with the aim of bringing forward the start of a potentially pivotal Phase 2 study, subject to receiving the necessary regulatory approvals.

Anyone out, or partially out, heading into next week is madness! Absolute madness.

Hello

· Following completion of the Anchois well, Energean will have the right to acquire a further 10% of Chariot's equity in the Lixus licence for:

o US$850 million gross development carry to first gas (including the US$85m gross carry)

o US$50 million 5-year zero coupon convertible loan note with a strike price of £20 adjusted down for dividends or issuance of three million Energean shares, at Chariot's option on FID

o 7% royalty payment on Energean's gas production revenues in excess of a base hurdle on the realised gas price (post transportation costs)

We are down! ENERGEAN good partner to have

>1b usd MC.

Back tested a couple of times. Should head back to 25p again now, then 30p

@jimmy et Al

Looks like Eni Topaz driller is still active in Morocco

Spud was early Sept and we are now into Dec.

Does length of time suggest success e.g. testing?

Does success have any impact for chariot?

Nice volune yesterday.

Another big round number after hours...

Decent volume and some large o trades.

Looks like a shake before news imo. MM happy to take >200k

Looks good here.

AS does like a Thursday RNS. I fully expect the big one to land on a Thursday.

Could easily boom 200%+ today.

I suspect this will run and run. Expect spike to 15p

Watched for a long time but in now. This has a long way to run

Spoke too soon -